<rst>
<header>
	<relations>
			<rel name="purpose" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="evidence" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="elaboration" type="rst"/>
			<rel name="antithesis" type="rst"/>
			<rel name="condition" type="rst"/>
			<rel name="concession" type="rst"/>
			<rel name="means" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="contrast" type="multinuc"/>
			<rel name="joint" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">5.</segment>
<segment id="2" parent="1002" relname="preparation">Conclusions and Perspectives</segment>
<segment id="3" parent="1002" relname="joint">EGFR-TKIs are currently the standard first-line treatment of patients with advanced NSCLC with activating EGFR mutations .</segment>
<segment id="4" parent="1002" relname="joint">These targeted therapies are usually well tolerated comparative to conventional chemotherapy .</segment>
<segment id="5" parent="1002" relname="joint">The self-oral administration of the drug positively contributes to improving patient compliance</segment>
<segment id="6" parent="1002" relname="joint">and reducing the use of hospital resources .</segment>
<segment id="7" parent="1007" relname="span">However , this non-invasive route of administration is also associated with unpredictable bioavailability , increased risk of drug interactions , and concerns about patient safety , surveillance , and follow-up .</segment>
<segment id="8" parent="7" relname="elaboration">Chronic EGFR-TKIs</segment>
<segment id="9" parent="1002" relname="joint">underdosage may favor the selection of resistant clones and thus disease progression ,</segment>
<segment id="10" parent="1002" relname="joint">and overdosage may increase the risk of dose-related side effects .</segment>
<segment id="11" parent="1011" relname="span">Self-administration also means that the severity of side effects can be considerably impacted by patient behavior</segment>
<segment id="12" parent="11" relname="elaboration">( e.g. , dietary habits , self-medicating , smoker status ) .</segment>
<segment id="13" parent="1013" relname="span">To date , EGFR-TKIs can be administered in advanced NSCLC for a long period of time ,</segment>
<segment id="14" parent="1014" relname="span">usually</segment>
<segment id="15" parent="1015" relname="contrast">until the disease progresses</segment>
<segment id="16" parent="1015" relname="contrast">or unacceptable toxicity occurs .</segment>
<segment id="17" parent="1002" relname="joint">As early intervention with supportive care strategies can minimize the intensity of adverse reactions</segment>
<segment id="18" parent="1017" relname="span">or allow for appropriate dose adjustments</segment>
<segment id="19" parent="1019" relname="span">without the need</segment>
<segment id="20" parent="19" relname="purpose">to discontinue treatment ,</segment>
<segment id="21" parent="1021" relname="joint">acute toxicity follow-up and side effect management is of major interest .</segment>
<segment id="22" parent="1023" relname="span">Therefore , medical oncologists should not only understand the AEs</segment>
<segment id="23" parent="22" relname="elaboration">associated with these drugs ,</segment>
<segment id="24" parent="1024" relname="span">but also develop the necessary skills</segment>
<segment id="25" parent="1025" relname="span">to detect and treat them</segment>
<segment id="26" parent="25" relname="purpose">to reduce morbidity and mortality as well as premature discontinuation of treatment .</segment>
<segment id="27" parent="1027" relname="joint">Patient education on these strategies is also of major importance</segment>
<segment id="28" parent="1028" relname="span">and can improve patient tolerance , quality of life , and overall treatment outcome</segment>
<segment id="29" parent="28" relname="means">by initiating supportive care soon after symptoms occur .</segment>
<segment id="30" parent="1029" relname="joint">Within this guidance and preventive strategy , the pharmacist can play a major role .</segment>
<segment id="31" parent="1031" relname="same_unit">Good knowledge of disease monitoring , response milestones , and the risks versus benefits of the treatment options</segment>
<segment id="32" parent="1032" relname="contrast">allows pharmacists to better advise patients</segment>
<segment id="33" parent="1032" relname="contrast">or counsel patients more effectively .</segment>
<segment id="34" parent="1034" relname="span">Nurses and prescribers are qualified</segment>
<segment id="35" parent="34" relname="purpose">to monitor toxicity risks as closely as possible .</segment>
<segment id="36" parent="1035" relname="joint">Unfortunately , they do not necessarily do so at regular intervals .</segment>
<segment id="37" parent="1037" relname="span">Patients can connect with pharmacists</segment>
<segment id="38" parent="1038" relname="span">who can provide them additional information or complementary recommendations on AEs</segment>
<segment id="39" parent="38" relname="circumstance">without the need for patients to rapidly contact prescribers .</segment>
<segment id="40" parent="1041" relname="circumstance">When more complex or serious AEs appear ,</segment>
<segment id="41" parent="1041" relname="span">pharmacists</segment>
<segment id="42" parent="41" relname="elaboration">who work closely with nurses and prescribers can propose the most appropriate therapeutic strategies .</segment>
<segment id="43" parent="1043" relname="span">Finally , medical oncologists</segment>
<segment id="44" parent="1044" relname="joint">able to understand AEs along with patient education and collaboration between different medical professional groups for therapeutic drug monitoring systems are needed ,</segment>
<segment id="45" parent="1044" relname="joint">but further research on the aforementioned methods of relief for continued TKI use should be also performed in the future .</segment>
<segment id="46" parent="1046" relname="span">The importance of proactive patient follow-up must be emphasized</segment>
<segment id="47" parent="46" relname="antithesis">rather than relying on self-reporting between clinical visits .</segment>
<segment id="48" parent="1050" relname="attribution">A randomized trial showed</segment>
<segment id="49" parent="1050" relname="span">that patients</segment>
<segment id="50" parent="49" relname="elaboration">receiving chemotherapy for advanced cancer ,</segment>
<segment id="51" parent="1049" relname="evidence">web-based symptom reporting with automated clinician e-mail alerts resulted in better health-related quality of life , fewer emergency room visits , fewer hospitalizations , and superior quality-adjusted survival .</segment>
<segment id="52" parent="1051" relname="joint">Recently , Cheema et al. assessed the impact of an interprofessional , proactive follow-up algorithm on the incidence of dose interruptions , reductions , and the severity of AEs in patients on afatinib .</segment>
<segment id="53" parent="54" relname="attribution">The authors reported</segment>
<segment id="54" parent="1053" relname="span">that over half of first AEs and one third of all grade 1-2 and grade ≥3 AEs were detected through proactive follow-up .</segment>
<segment id="55" parent="1054" relname="joint">This multi-disciplinary AE algorithm resulted in a low rate of costly emergency room or urgent clinic visits and a reduced incidence of severe drug-related AEs and discontinuation therapy .</segment>
<segment id="56" parent="1056" relname="same_unit">In conclusion ,</segment>
<segment id="57" parent="58" relname="circumstance">when closely monitoring patients ,</segment>
<segment id="58" parent="1057" relname="span">the ability of clinicians to make rapid therapeutic decisions in the event of medical complications is critical in the diagnosis and management of TKI-related side effects .</segment>
<segment id="59" parent="1058" relname="span">This is even more decisive in the event of serious or even life-threatening complications .</segment>
<segment id="60" parent="1060" relname="joint">However , good clinician – patient communication , drug patient education , early detection and management of drug side effects ,</segment>
<segment id="61" parent="1060" relname="joint">and monitoring of disease response with plasma concentration quantification can also improve patient outcomes .</segment>
<segment id="62" parent="1061" relname="span">Close cooperation between oncologists , internists , pharmaceutics , and nurses should become the gold standard in the comprehensive clinical care of advanced NSCLC patients</segment>
<segment id="63" parent="62" relname="elaboration">receiving TKIs .</segment>
<group id="1000" type="span" />
<group id="1001" type="span" parent="1000" relname="span"/>
<group id="1002" type="multinuc" parent="1001" relname="span"/>
<group id="1007" type="span" parent="1002" relname="joint"/>
<group id="1011" type="span" parent="1002" relname="joint"/>
<group id="1013" type="span" parent="1002" relname="joint"/>
<group id="1014" type="span" parent="13" relname="elaboration"/>
<group id="1015" type="multinuc" parent="14" relname="condition"/>
<group id="1017" type="span" parent="1002" relname="joint"/>
<group id="1018" type="multinuc" parent="18" relname="circumstance"/>
<group id="1019" type="span" parent="1018" relname="joint"/>
<group id="1020" type="multinuc" parent="1018" relname="joint"/>
<group id="1021" type="multinuc" parent="1020" relname="joint"/>
<group id="1022" type="span" parent="1021" relname="joint"/>
<group id="1023" type="span" parent="1024" relname="concession"/>
<group id="1024" type="span" parent="1022" relname="span"/>
<group id="1025" type="span" parent="24" relname="purpose"/>
<group id="1026" type="multinuc" parent="1020" relname="joint"/>
<group id="1027" type="multinuc" parent="1026" relname="joint"/>
<group id="1028" type="span" parent="1027" relname="joint"/>
<group id="1029" type="multinuc" parent="1026" relname="joint"/>
<group id="1030" type="multinuc" parent="1029" relname="joint"/>
<group id="1031" type="multinuc" parent="1030" relname="joint"/>
<group id="1032" type="multinuc" parent="1031" relname="same_unit"/>
<group id="1033" type="multinuc" parent="1030" relname="joint"/>
<group id="1034" type="span" parent="1033" relname="joint"/>
<group id="1035" type="multinuc" parent="1033" relname="joint"/>
<group id="1036" type="multinuc" parent="1035" relname="joint"/>
<group id="1037" type="span" parent="1036" relname="joint"/>
<group id="1038" type="span" parent="37" relname="elaboration"/>
<group id="1039" type="multinuc" parent="1036" relname="joint"/>
<group id="1040" type="span" parent="1039" relname="joint"/>
<group id="1041" type="span" parent="1040" relname="span"/>
<group id="1042" type="multinuc" parent="1039" relname="joint"/>
<group id="1043" type="span" parent="1042" relname="joint"/>
<group id="1044" type="multinuc" parent="43" relname="elaboration"/>
<group id="1045" type="multinuc" parent="1042" relname="joint"/>
<group id="1046" type="span" parent="1045" relname="joint"/>
<group id="1047" type="multinuc" parent="1045" relname="joint"/>
<group id="1048" type="span" parent="1047" relname="joint"/>
<group id="1049" type="span" parent="1048" relname="span"/>
<group id="1050" type="span" parent="1049" relname="span"/>
<group id="1051" type="multinuc" parent="1047" relname="joint"/>
<group id="1052" type="multinuc" parent="1051" relname="joint"/>
<group id="1053" type="span" parent="1052" relname="joint"/>
<group id="1054" type="multinuc" parent="1052" relname="joint"/>
<group id="1055" type="multinuc" parent="1054" relname="joint"/>
<group id="1056" type="multinuc" parent="1055" relname="joint"/>
<group id="1057" type="span" parent="1056" relname="same_unit"/>
<group id="1058" type="span" parent="1055" relname="joint"/>
<group id="1059" type="multinuc" parent="59" relname="elaboration"/>
<group id="1060" type="multinuc" parent="1059" relname="joint"/>
<group id="1061" type="span" parent="1059" relname="joint"/>
	</body>
</rst>
